Press Releases

News & Media

Motus GI Expands Intellectual Property Portfolio with Issuance of New U.S. Patent for the Pure-Vu® System

Issued patent further bolsters Company’s intellectual property
estate, supporting strategic pathway for Pure-Vu®
System to become standard of care for inpatient colonoscopy

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--
Motus
GI Holdings, Inc., (NASDAQ: MOTS)
("Motus GI" or the "Company"), a medical technology company dedicated to
improving clinical outcomes and enhancing the cost-efficiency of
colonoscopy, announced today that the U.S. Patent and Trademark Office
(USPTO) has issued patent No. 10,179,202 titled, “Systems and methods
for cleaning body cavities and for endoscopic steering,” which
protects the Company’s flagship product, the Pure-Vu®
System.

The Pure-Vu® System is a U.S. Food and Drug Administration
(“FDA”) cleared medical device indicated to help facilitate the cleaning
of a poorly prepared colon during the colonoscopy procedure. The device
integrates with standard and slim colonoscopes to enable safe and rapid
cleansing during the procedure while preserving established procedural
workflow and techniques.

“We continue to add to our extensive IP portfolio which is now comprised
of over 20 patents worldwide, covering all aspects of the Pure-Vu®
System. Intellectual property continues to be a key focus, particularly
as we prepare for the commercial launch of Pure-Vu® next
quarter,” commented Tim
Moran, Chief Executive Officer of Motus GI. “To complement our
strong IP portfolio, we are actively generating robust clinical data
which we believe demonstrates the Pure-Vu® System’s ability
to reduce the number of delayed and incomplete procedures in the
inpatient setting, a significant issue where more than half of patients
present with an insufficiently prepped colon, leading to additional
costs. Our ongoing REDUCE study is evaluating the Pure-Vu®
System’s ability to consistently and reliably cleanse the colon to
facilitate a successful colonoscopy in a timely manner in patients who
are indicated for a diagnostic colonoscopy.”

About Motus GI and the Pure-Vu® System

Motus GI Holdings, Inc. is a medical technology company, with
subsidiaries in the U.S. and Israel, dedicated to improving clinical
outcomes and enhancing the cost-efficiency of colonoscopy. The Company’s
flagship product is the Pure-Vu® System, a U.S. FDA cleared
medical device indicated to help facilitate the cleaning of a poorly
prepared colon during the colonoscopy procedure. The device integrates
with standard and slim colonoscopes to enable safe and rapid cleansing
during the procedure while preserving established procedural workflow
and techniques. The Pure-Vu® System has received CE mark
approval in Europe. The Pure-Vu® System is currently being
introduced on a pilot basis in the U.S. market, and the Company is
planning to initiate a full commercial launch focused on the inpatient
colonoscopy market in the U.S. and select international markets in 2019.
Challenges with bowel preparation for inpatient colonoscopy represent a
significant area of unmet need that directly affects clinical outcomes
and increases the cost of care in a market segment that comprises
approximately 1.5 million annual procedures in the U.S. and
approximately 4 million annual procedures worldwide. Motus GI believes
the Pure-Vu® System may improve outcomes and lower costs for
hospitals by reducing the time to successful colonoscopy, minimizing
delayed and incomplete procedures, and improving the quality of an exam.
In clinical studies to date, the Pure-Vu® System
significantly increased the number of patients with an adequate
cleansing level, according to the Boston Bowel Preparation Scale Score,
a validated assessment instrument.

This press release contains certain forward-looking statements.
Forward-looking statements are based on the Company's current
expectations and assumptions. The Private Securities Litigation Reform
Act of 1995 provides a safe-harbor for forward-looking statements. These
statements may be identified by the use of forward-looking expressions,
including, but not limited to, "expect," "anticipate," "intend," "plan,"
"believe," "estimate," "potential," "predict," "project," "should,"
"would" and similar expressions and the negatives of those terms,
including without limitation, risks inherent in the development and
commercialization of potential products, uncertainty in the timing and
results of clinical trials or regulatory approvals, maintenance of
intellectual property rights or other risks discussed in the Company’s
Form 10-K filed on March 28, 2018, and its other filings with the
Securities and Exchange Commission. Prospective investors are cautioned
not to place undue reliance on such forward-looking statements, which
speak only as of the date hereof. The Company undertakes no obligation
to publicly update any forward-looking statement, whether as a result of
new information, future events or otherwise.